These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29331155)

  • 21. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
    Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
    Patel N; Harrington S; Dihmess A; Woo B; Masoud R; Martis P; Fiorenza M; Graffunder E; Evans A; McNutt LA; Lodise TP
    J Antimicrob Chemother; 2011 Jul; 66(7):1600-8. PubMed ID: 21508008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of formulary restriction on the relative consumption of carbapenems in intensive care units at an academic medical center.
    Pierce JW; Kirk A; Lee KB; Markley JD; Pakyz A; Bearman G; Doll ME; Stevens MP
    Infect Control Hosp Epidemiol; 2019 Sep; 40(9):1056-1058. PubMed ID: 31232265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes.
    Seah VXF; Ong RYL; Lim ASY; Chong CY; Tan NWH; Thoon KC
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network.
    Rhodes NJ; Wagner JL; Davis SL; Bosso JA; Goff DA; Rybak MJ; Scheetz MH;
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.
    Horii T; Muramatsu H; Morita M; Maekawa M
    Microb Drug Resist; 2003; 9(2):223-9. PubMed ID: 12820809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
    Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
    Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
    Horikoshi Y; Higuchi H; Suwa J; Isogai M; Shoji T; Ito K
    J Infect Chemother; 2016 Aug; 22(8):532-5. PubMed ID: 27263807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of appropriate carbapenem prescribing in stewardship programmes.
    Canouï E; Gauzit R; Bruneau A; Alviset S; Hays C; Charpentier J; Batista R; Kernéis S
    J Hosp Infect; 2018 Nov; 100(3):277-279. PubMed ID: 29614244
    [No Abstract]   [Full Text] [Related]  

  • 30. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
    Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496
    [No Abstract]   [Full Text] [Related]  

  • 31. Nosocomial transmission of carbapenem-resistant Pseudomonas aeruginosa among burn patients.
    Maillet M; Pelloux I; Forli A; Vancoetsem K; Cheong Sing JS; Marfaing S; Ducki S; Batailler P; Mallaret MR
    Infect Control Hosp Epidemiol; 2014 May; 35(5):597-9. PubMed ID: 24709737
    [No Abstract]   [Full Text] [Related]  

  • 32. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
    Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
    Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

  • 34. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
    Mladenovic-Antic S; Kocic B; Velickovic-Radovanovic R; Dinic M; Petrovic J; Randjelovic G; Mitic R
    J Clin Pharm Ther; 2016 Oct; 41(5):532-7. PubMed ID: 27511808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.
    Chiotos K; Tamma PD; Flett KB; Naumann M; Karandikar MV; Bilker WB; Zaoutis T; Han JH
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill.
    Teshome BF; Vouri SM; Hampton NB; Kollef MH; Micek ST
    Infect Control Hosp Epidemiol; 2020 Apr; 41(4):484-485. PubMed ID: 31983358
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
    Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between carbapenem use, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii.
    Apisarnthanarak A; Jitpokasem S; Mundy LM
    Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1235-7. PubMed ID: 24113616
    [No Abstract]   [Full Text] [Related]  

  • 39. Accuracy of Provider-Selected Indications for Antibiotic Orders.
    Heil EL; Pineles L; Mathur P; Morgan DJ; Harris AD; Srinivasan A; Thom KA;
    Infect Control Hosp Epidemiol; 2018 Jan; 39(1):111-113. PubMed ID: 29345611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains.
    Tsai MH; Wu TL; Su LH; Lo WL; Chen CL; Liang YH; Chiu CH
    Int J Antimicrob Agents; 2014 Dec; 44(6):541-5. PubMed ID: 25264129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.